This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Y-mAbs Therapeutics Future Growth
Future criteria checks 1/6
Y-mAbs Therapeutics's earnings are forecast to decline at 4.4% per annum while its annual revenue is expected to grow at 18.1% per year. EPS is expected to grow by 1.4% per annum. Return on equity is forecast to be -74.9% in 3 years.
Key information
-4.4%
Earnings growth rate
1.38%
EPS growth rate
| Biotechs earnings growth | 25.2% |
| Revenue growth rate | 18.1% |
| Future return on equity | -74.93% |
| Analyst coverage | Good |
| Last updated | 05 Sep 2025 |
Recent future growth updates
Analysis Article • May 16
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) came out with a strong set of first-quarter numbers that could...Analysis Article • Mar 07
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders are probably feeling a little disappointed, since its shares...Recent updates
Seeking Alpha • Aug 06
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A
Summary Y-mAbs Therapeutics announced that it would be acquired at a >100% premium relative to recent trading. The deal showcases how little optimism there is in the biotech market at this time, even though recent investors are seeing substantial gains. This article lays out what SERB is going to get, and what I feel this transaction means for near-term biotech M&A. Read the full article on Seeking Alpha
Narrative Update • Aug 06
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
Despite improved profitability—with net profit margin rising to 12.26% and a lower future P/E of 47.56x—analysts have cut Y-mAbs Therapeutics’ consensus price target from $14.70 to $11.68, suggesting tempered growth expectations. What's in the News SERB S.A.S. agreed to acquire Y-mAbs Therapeutics for approximately $398.67 million ($8.6 per share); deal approved by Y-mAbs board and expected to close by December 31, 2025, subject to antitrust approval.Analysis Article • May 16
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) came out with a strong set of first-quarter numbers that could...Analysis Article • Apr 29
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price
Y-mAbs Therapeutics, Inc.'s ( NASDAQ:YMAB ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong...
New Narrative • Mar 31
DANYELZA And Radiopharmaceuticals Realignment Will Energize Global Opportunities
Strategic realignment into DANYELZA and Radiopharmaceuticals could enhance revenue growth and operational efficiency through focused business units.Analysis Article • Mar 07
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders are probably feeling a little disappointed, since its shares...Seeking Alpha • Jan 24
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Summary YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for assessing the viability of their radiotherapy platform, most notably concerns related to toxicity. Despite risks, YMAB's current market cap of $270 million may be a bargain if upcoming data provides a clear clinical direction. I reiterate a "Buy" sentiment, with reservations about naxitamab sales growth and the uncertain future of GD2-SADA. Read the full article on Seeking AlphaAnalysis Article • Jan 10
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares are down a considerable 26% in...Analysis Article • Dec 10
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Nov 19
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Oct 21
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Summary Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million and a cash runway of 4-5 quarters, raising concerns about its ability to fund future R&D. The company is focusing on the SADA platform, but the lack of efficacy data makes it a speculative investment at this stage. Despite promising prospects, YMAB's low cash reserves and small market potential for naxitamab warrant a cautious investment approach. Read the full article on Seeking AlphaAnalysis Article • Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have had a really impressive month, gaining 33% after a shaky period...Seeking Alpha • Aug 12
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Summary YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters. Read the full article on Seeking AlphaAnalysis Article • Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysis Article • Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
The Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • May 09
Y-mAbs: There's A Ceiling Here Somewhere
Summary Y-mAbs Therapeutics has experienced a significant recovery in value but lacks upcoming catalysts for near-term growth. Their approved therapy, naxitamab, has shown promising results in treating pediatric cancers. Y-mAbs' GD2-SADA pipeline project has potential but carries high risk, and the company's financials are stable for now. Read the full article on Seeking AlphaAnalysis Article • Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Y-mAbs...Analysis Article • Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have continued their recent momentum with a 66% gain in the last month...Seeking Alpha • Jan 14
Y-mAbs Therapeutics: A Monoclonal Antibody Play
Summary Y-mAbs Therapeutics' shares have rebounded massively since March 2023 due to the company's restructuring, extending its cash runway until 2027. The company's main commercial asset is Danyelza, a monoclonal antibody for the treatment of neuroblastoma, which has shown promising sales. Y-mAbs is also evaluating Danyelza for other indications and has a novel cancer treatment program called SADA, but these are still in early stages. Chase the rally or time to take some profits? A full investment analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 109 | -59 | -67 | -60 | 7 |
| 12/31/2026 | 95 | -49 | -54 | -20 | 9 |
| 12/31/2025 | 83 | -30 | -39 | -26 | 10 |
| 6/30/2025 | 85 | -22 | -18 | -18 | N/A |
| 3/31/2025 | 89 | -28 | -19 | -19 | N/A |
| 12/31/2024 | 88 | -30 | -16 | -16 | N/A |
| 9/30/2024 | 85 | -24 | -22 | -22 | N/A |
| 6/30/2024 | 87 | -25 | -13 | -13 | N/A |
| 3/31/2024 | 84 | -22 | -18 | -18 | N/A |
| 12/31/2023 | 85 | -21 | -27 | -27 | N/A |
| 9/30/2023 | 93 | -19 | -28 | -28 | N/A |
| 6/30/2023 | 85 | -39 | -46 | -46 | N/A |
| 3/31/2023 | 75 | -74 | -64 | -64 | N/A |
| 12/31/2022 | 65 | -96 | -76 | -76 | N/A |
| 9/30/2022 | 43 | -134 | -102 | -101 | N/A |
| 6/30/2022 | 40 | -135 | -100 | -100 | N/A |
| 3/31/2022 | 40 | -117 | -96 | -96 | N/A |
| 12/31/2021 | 35 | -55 | -104 | -103 | N/A |
| 9/30/2021 | 46 | -38 | -87 | -86 | N/A |
| 6/30/2021 | 37 | -42 | -93 | -92 | N/A |
| 3/31/2021 | 26 | -60 | -102 | -101 | N/A |
| 12/31/2020 | 21 | -119 | -91 | -91 | N/A |
| 9/30/2020 | N/A | -123 | -99 | -98 | N/A |
| 6/30/2020 | N/A | -114 | -97 | -95 | N/A |
| 3/31/2020 | N/A | -91 | -84 | -82 | N/A |
| 12/31/2019 | N/A | -81 | -75 | -73 | N/A |
| 9/30/2019 | N/A | -72 | -63 | -62 | N/A |
| 6/30/2019 | N/A | -59 | -51 | -50 | N/A |
| 3/31/2019 | N/A | -52 | N/A | -48 | N/A |
| 12/31/2018 | N/A | -43 | N/A | -41 | N/A |
| 9/30/2018 | N/A | -38 | N/A | -34 | N/A |
| 6/30/2018 | N/A | -31 | N/A | -27 | N/A |
| 3/31/2018 | N/A | -24 | N/A | -19 | N/A |
| 12/31/2017 | N/A | -19 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YMAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YMAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YMAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YMAB's revenue (18.1% per year) is forecast to grow faster than the US market (9.6% per year).
High Growth Revenue: YMAB's revenue (18.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YMAB is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/15 09:58 |
| End of Day Share Price | 2025/09/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Y-mAbs Therapeutics, Inc. is covered by 8 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Thomas Shrader | BTIG |